The global acromegaly treatment market size was valued at USD 1.63 billion in 2024 and is projected to grow at a CAGR of 6.4% from 2025 to 2030, driven by the rising prevalence and earlier diagnosis of acromegaly.Improved awareness, enhanced diagnostic tools such as MRI and IGF-1 tests, and a better understanding of symptoms have led to more timely diagnoses. Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.
In addition, the surging demand for personalized medicine is accelerating the acromegaly treatment industry by enabling tailored therapies that offer more effective, individualized care. Advances in genomics and diagnostics allow for precision treatments, improving patient outcomes and satisfaction. Moreover, better patient access to healthcare, especially in emerging markets, is expanding the reach of acromegaly therapies. Improved healthcare infrastructure, greater insurance coverage, and enhanced diagnostic tool availability enable more patients to seek treatment. These factors increase treatment adoption and foster market growth by broadening patient access to innovative therapies.
The somatostatin analogues (SSAs) segment captured the largest market share of 65.0% in 2024, owing to their effectiveness in controlling growth hormone levels and managing symptoms. SSAs such as octreotide, lanreotide, and pasireotide have become the standard of care, significantly improving patient quality of life. Their ability to reduce tumor size and normalize hormone levels has made them the preferred choice for long-term management of acromegaly. In addition, supportive government policies and reimbursement programs have further solidified the dominance of SSAs in the market.
Moreover, the growth hormone receptor antagonists (GHRAs) segment is poised to register the fastest CAGR of 7.0% between 2025 and 2030 due to their targeted approach to blocking the action of growth hormones at the receptor level. GHRAs, such as pegvisomant, effectively manage acromegaly symptoms by normalizing insulin-like growth factor 1 (IGF-1) levels. The escalating prevalence of acromegaly and the demand for advanced treatment options are driving the growth of this segment. Besides, ongoing research and development efforts are expected to introduce new and improved GHRAs, further expanding their market presence.
The hospital pharmacies segment garnered the largest share of 49.8% in 2024, attributed to their critical role in providing immediate and specialized care. Hospital pharmacies ensure the availability of advanced medications, such as somatostatin analogs and growth hormone receptor antagonists, essential for effective acromegaly management. Their proximity to healthcare providers allows for timely administration and monitoring of treatments, leading to better patient outcomes. In addition, hospital pharmacies often have the infrastructure to handle complex therapies, making them the preferred choice for acromegaly treatment.
The retail pharmacies segment is anticipated to emerge as the fastest-growing segment and record a CAGR of 6.4% over the forecast period, spurred by their widespread accessibility and convenience. Patients benefit from easier access to necessary medications, enhancing adherence to prescribed therapies. Retail pharmacies offer personalized services, such as patient counseling and medication management, improving treatment outcomes. The expansion of retail pharmacies into specialty medications and partnerships with healthcare providers ensures comprehensive care for chronic conditions such as acromegaly.
North America acromegaly treatment market recorded the largest share of 38.7% in 2024, due to the region’s advanced healthcare infrastructure, high awareness levels, and access to cutting-edge treatments. The region's strong diagnostic capabilities enable early detection of acromegaly, leading to timely treatment and better patient outcomes. Besides, the presence of major pharmaceutical companies drives innovation in drug development, particularly in somatostatin analogs and growth hormone receptor antagonists. With comprehensive healthcare coverage, including insurance plans, North American patients have greater access to medical therapies and surgical interventions, solidifying the region’s leading position in the global market.
The acromegaly treatment market in U.S. achieved a dominating share in 2024, propelled by its advanced healthcare infrastructure, extensive research and development efforts, and significant disease prevalence. The country benefits from ample investments in innovative therapies and state-of-the-art medical technologies. Besides, high awareness levels among healthcare providers and patients and supportive insurance policies and government initiatives for rare diseases have facilitated early diagnosis and effective treatment.
Strong healthcare infrastructure, advanced diagnostic capabilities, and growing awareness of rare diseases will make Canada a crucial market contributor by 2030. Focusing on patient-centered care, Canada ensures widespread access to effective treatments, including somatostatin analogs and surgical interventions. The country’s high-quality healthcare system, backed by government support, facilitates early diagnosis and long-term management of acromegaly. Moreover, ongoing research and the introduction of new therapies will further contribute to the market’s growth.
Europe acromegaly treatment market is expected to experience a significant growth rate over the forecast period, attributed to the region’s advanced healthcare infrastructure, ample investment in medical research, and high prevalence of the disease. Countries such as Germany, France, and the UK have made substantial progress in developing innovative treatments and diagnostic tools. The region benefits from strong collaboration between academic institutions, research centers, and pharmaceutical companies. In addition, supportive government policies and healthcare systems ensure early diagnosis and comprehensive treatment for patients, contributing to the region's leading position in the acromegaly treatment market.
The UK is set to record a noteworthy CAGR over the forecast period, spurred by its advanced healthcare system, sizable investment in medical research, and high disease prevalence. The country's focus on developing innovative therapies and diagnostic tools has been pivotal. Collaboration between top universities, research institutions, and pharmaceutical companies further accelerates progress. Moreover, the NHS supports early diagnosis and comprehensive treatment, ensuring patients receive timely care.
Germany acromegaly treatment market is anticipated to establish a notable presence in the acromegaly treatment market in the coming years, propelled by its robust healthcare infrastructure, extensive medical research, and innovative treatment approaches. The country's commitment to developing advanced therapies and diagnostic tools is key. Collaborative efforts between leading universities, research institutions, and pharmaceutical companies are accelerating progress. Strong government support and healthcare policies also enhance early diagnosis and treatment accessibility.
APAC acromegaly treatment market is set to witness the fastest CAGR of 8.0% over the forecast period, fueled by its rapid economic growth, increasing healthcare investments, and advancements in medical infrastructure. Rising awareness about acromegaly is leading to earlier diagnoses and a burgeoning demand for effective treatments. The large population and significant unmet medical needs present vast opportunities for market expansion. Furthermore, supportive government policies and initiatives encourage pharmaceutical investments and research, enhancing the development and availability of advanced therapies across the region.
Asia Pacific is poised to witness a remarkable CAGR over the forecast period, owing to fast-paced economic growth, increasing healthcare investments, and advanced medical infrastructure. Rising awareness about acromegaly has led to earlier diagnoses and a surging demand for effective treatments. Government initiatives and supportive regulations have encouraged pharmaceutical investments and research, enhancing the development and availability of advanced therapies.
Japan is projected to grow at a substantial CAGR from 2025 to 2030, driven by its state-of-the-art healthcare framework, robust medical facilities, and heightened emphasis on rare diseases. With a rising awareness of acromegaly, especially among the aging population, the demand for effective treatments is expanding. The country's strong pharmaceutical industry and government initiatives to improve healthcare access ensure the availability of therapies such as somatostatin analogs and surgical options. Moreover, ongoing innovations and research in acromegaly treatment are expected to boost the market further, making Japan a key region for future growth.
China acromegaly treatment market captured a considerable share in 2024, attributed to its rapidly advancing healthcare system, increasing healthcare investments, and growing awareness of rare diseases. With a vast population and improved access to diagnostic tools, early detection and treatment of acromegaly are becoming more common. The government’s focus on expanding healthcare coverage and improving medical infrastructure has enhanced the availability of treatments such as somatostatin analogs and surgical options. Furthermore, the rise of domestic pharmaceutical companies and better access to innovative therapies have solidified China’s dominance in the market.
Some of the key companies in the acromegaly treatment market include Novartis AG, Ipsen Pharma, Sun Pharmaceutical Industries Ltd, Chiasma, Inc., Peptron, Inc., WOCKHARDT, Dauntless Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, Inc., and others.
Novartis AG focuses on developing treatments for serious conditions such as cancer, cardiovascular diseases, and metabolic disorders. They strive to bring transformative therapies to patients worldwide.
Ipsen Pharma specializes in oncology, rare diseases, and neuroscience and is dedicated to providing therapies for high unmet medical needs, with a strong emphasis on patient well-being and scientific excellence.
The following are the leading companies in the acromegaly treatment market. These companies collectively hold the largest market share and dictate industry trends.
View a comprehensive list of companies in the Acromegaly Treatment Market
In September 2024, Crinetics Pharmaceuticals submitted a New Drug Application (NDA) to the FDA for paltusotine, a first-of-its-kind, once-daily, oral somatostatin receptor type 2 nonpeptide agonist. Paltusotine is being developed as a treatment and long-term maintenance therapy for acromegaly.
In August 2024, Crinetics is preparing for a 2025 U.S. launch of its acromegaly treatment and is launching a new campaign to raise awareness about the condition.
Report Attribute |
Details |
Market size value in 2025 |
USD 1.74 billion |
Revenue forecast in 2030 |
USD 2.37 billion |
Growth rate |
CAGR of 6.4% from 2025 to 2030 |
Base year for estimation |
2024 |
Historical data |
2018 - 2024 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Drug class, distribution channel, region |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Norway, Sweden, Japan, China, India, South Korea, Australia, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait |
Key companies profiled |
Novartis AG, Ipsen Pharma, Sun Pharmaceutical Industries Ltd, Chiasma, Inc., Peptron, Inc., WOCKHARDT, Dauntless Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global acromegaly treatment market report on the basis of drug class, distribution channel, and region:
Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
Somatostatin Analogues (SSAs)
Growth Hormone Receptor Antagonists (GHRAs)
Dopamine Agonists
Others
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Norway
Sweden
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Kuwait
"The quality of research they have done for us has been excellent."